Past, Present, and Future of Therapies for Pituitary Neuroendocrine Tumors: Need for Omics and Drug Repositioning Guidance


Aydin B., Yildirim E., ERDOĞAN O., ARĞA K. Y., Yilmaz B., BOZKURT S., ...Daha Fazla

OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY, cilt.26, sa.3, ss.115-129, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 26 Sayı: 3
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1089/omi.2021.0221
  • Dergi Adı: OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.115-129
  • Anahtar Kelimeler: pituitary neuroendocrine tumors, pituitary adenoma, systems medicine, drug repositioning, omics, personalized medicine, GLUCOCORTICOID-RECEPTOR ANTAGONIST, LONG-TERM TREATMENT, LOW-DOSE ETOMIDATE, CUSHINGS-SYNDROME, GROWTH-HORMONE, MEDICAL-TREATMENT, EUROPEAN-SOCIETY, ADENOMAS, DISEASE, MANAGEMENT
  • Marmara Üniversitesi Adresli: Evet

Özet

Innovation roadmaps are important, because they encourage the actors in an innovation ecosystem to creatively imagine multiple possible science future(s), while anticipating the prospects and challenges on the innovation trajectory. In this overarching context, this expert review highlights the present unmet need for therapeutic innovations for pituitary neuroendocrine tumors (PitNETs), also known as pituitary adenomas. Although there are many drugs used in practice to treat PitNETs, many of these drugs can have negative side effects and show highly variable outcomes in terms of overall recovery. Building innovation roadmaps for PitNETs' treatments can allow incorporation of systems biology approaches to bring about insights at multiple levels of cell biology, from genes to proteins to metabolites. Using the systems biology techniques, it will then be possible to offer potential therapeutic strategies for the convergence of preventive approaches and patient-centered disease treatment. Here, we first provide a comprehensive overview of the molecular subtypes of PitNETs and therapeutics for these tumors from the past to the present. We then discuss examples of clinical trials and drug repositioning studies and how multi-omics studies can help in discovery and rational development of new therapeutics for PitNETs. Finally, this expert review offers new public health and personalized medicine approaches on cases that are refractory to conventional treatment or recur despite currently used surgical and/or drug therapy.